object
studi
conduct
investig
correl
antibiot
consumpt
incid
healthcareassoci
infect
hcai
caus
methicillinresist
staphylococcu
aureu
mrsa
hcaimrsa
vancomycinresist
enterococci
vre
hcaivr
univers
hospit
taiwan
period
method
data
annual
patientday
annual
consumpt
defin
daili
patientday
glycopeptid
vancomycin
teicoplanin
linezolid
fusid
acid
tigecyclin
daptomycin
analyz
yearli
aggreg
data
number
nondupl
clinic
mrsa
vre
isol
caus
hcai
collect
journal
microbiolog
immunolog
infect
aureu
result
overal
consumpt
teicoplanin
linezolid
significantli
increas
studi
period
signific
decreas
incid
hcaimrsa
signific
increas
incid
hcaivr
found
studi
period
signific
correl
found
increas
use
teicoplanin
linezolid
decreas
incid
hcaimrsa
contrast
posit
correl
found
consumpt
teicoplanin
tigecyclin
incid
hcaivr
conclus
studi
identifi
variou
correl
consumpt
antibiot
incid
hcaimrsa
hcaivr
strict
implement
infectioncontrol
guidelin
reinforc
administ
appropri
antibiot
agent
would
help
decreas
incid
mrsa
vre
hospit
incid
healthcareassoci
infect
hcai
caus
multidrugresist
bacteria
gradual
risen
last
decad
especi
immunocompromis
patient
common
caus
agent
hcai
unit
state
gramposit
bacteria
staphylococcu
aureu
enterococcu
methicillin
oxacillin
resist
aureu
mrsa
particular
concern
patient
mrsa
infect
tend
higher
mortal
rate
longer
hospit
stay
higher
healthcareassoci
cost
patient
methicillinsuscept
aureu
infect
addit
diazgranado
et
al
found
mortal
rate
among
patient
vancomycinresist
enterococci
vre
infect
significantli
higher
among
patient
vancomycinsuscept
enterococcu
infect
taiwan
except
vre
mrsa
infect
becom
emerg
infecti
diseas
antibiot
use
one
risk
factor
antibiot
resist
among
bacteri
speci
howev
natur
relationship
complic
although
sever
studi
examin
relationship
antimicrobi
consumpt
antibiot
resist
find
inconsist
possibl
due
differ
resist
profil
well
due
differ
antibioticprescrib
practic
differ
countri
studi
use
glycopeptid
extendedspectrum
cephalosporin
fluoroquinolon
demonstr
associ
preval
mrsa
vre
studi
howev
investig
relationship
use
linezolid
fusid
acid
preval
mrsa
vre
addit
associ
consumpt
tigecyclin
novel
antigramposit
agent
deriv
minocyclin
shown
effect
mani
gramneg
rod
well
gramposit
cocci
preval
mrsa
vre
never
studi
similarli
studi
far
investig
associ
preval
mrsa
vre
consumpt
daptomycin
antimrsa
antibiot
approv
us
food
drug
administr
treatment
complic
skin
skinstructur
infect
bacteremia
due
mrsa
studi
investig
correl
consumpt
antibiot
includ
vancomycin
teicoplanin
linezolid
tigecyclin
fusid
acid
daptomycin
incid
hcaimrsa
hcaivr
period
medic
center
taiwan
nation
taiwan
univers
hospit
ntuh
academ
affili
medic
center
provid
primari
tertiari
care
northern
taiwan
number
annual
inpatientday
hospit
increas
linezolid
fusid
acid
introduc
hospit
formulari
tigecyclin
daptomycin
prescrib
ntuh
sinc
respect
data
analyz
studi
includ
previou
studi
bacteri
isol
data
suscept
aureu
oxacillin
collect
period
isol
nondupl
isol
speci
patient
recov
within
day
consid
singl
isol
suscept
test
aureu
enterococcu
speci
follow
clinic
laboratori
standard
institut
guidelin
aureu
atcc
use
control
strain
routin
disksuscept
test
methicillin
resist
among
aureu
isol
routin
screen
measur
growth
oxacillin
mgl
naclcontain
trypticas
soy
agar
plate
incub
ambient
air
c
hour
vancomycin
resist
among
enterococcu
speci
confirm
growth
isol
brain
heart
infus
agar
plate
contain
vancomycin
mgl
incub
ambient
air
c
hour
yearli
aggreg
data
number
nondupl
clinic
mrsa
vre
isol
caus
hcai
collect
hcai
defin
accord
nation
nosocomi
infect
surveil
guidelin
incid
rate
hcaimrsa
hcaivr
defin
number
patient
hcaimrsa
hcaivr
respect
per
inpatientday
data
annual
consumpt
defin
daili
dose
ddd
inpatientday
glycopeptid
vancomycin
teicoplanin
linezolid
fusid
acid
tigecyclin
daptomycin
obtain
pharmaci
depart
hospit
linear
regress
analysi
use
analyz
trend
annual
consumpt
antimicrobi
agent
trend
incid
hcaimrsa
hcaivr
time
pearson
product
moment
correl
coeffici
use
determin
relationship
annual
antibiot
consumpt
trend
resist
p
valu
consid
statist
signific
gener
use
antimicrobi
agent
vari
time
tabl
overal
consumpt
teicoplanin
linezolid
significantli
increas
wherea
consumpt
vancomycin
glycopeptid
includ
vancomycin
teicoplanin
tigecyclin
fusid
acid
remain
stabl
studi
period
trend
hcai
due
mrsa
vre
incid
hcaimrsa
hcaivr
period
studi
period
total
nondupl
aureu
isol
enterococc
isol
caus
hcai
identifi
fig
show
trend
mrsa
isol
incid
hcaimrsa
signific
decreas
incid
hcaimrsa
time
fig
show
trend
vre
isol
incid
hcaivr
signific
rise
incid
hcaivr
time
note
data
correl
incid
hcaimrsa
incid
hcaivr
annual
consumpt
vancomycin
teicoplanin
linezolid
fusid
acid
tigecyclin
daptomycin
shown
tabl
signific
correl
found
increas
use
linezolid
teicoplanin
decreas
preval
mrsa
contrast
signific
correl
found
increas
use
vancomycin
glycopeptid
vancomycin
teicoplanin
tigecyclin
fusid
acid
incid
hcaimrsa
howev
posit
correl
incid
hcaivr
use
teicoplanin
tigecyclin
studi
evalu
associ
antibiot
consumpt
incid
hcaimrsa
hcaivr
medic
center
taiwan
period
analyz
diseas
densiti
per
patientday
due
resist
bacteria
rather
resist
rate
paramet
densiti
consid
appropri
present
real
situat
addit
evalu
two
newli
avail
antibiot
tigecyclin
daptomycin
relationship
diseas
densiti
use
new
analysi
ad
new
data
sever
signific
novel
find
found
consumpt
teicoplanin
linezolid
significantli
increas
studi
period
howev
consumpt
vancomycin
glycopeptid
vancomycin
teicoplanin
fusid
acid
remain
stabl
specul
physician
hospit
like
prescrib
teicoplanin
linezolid
vancomycin
treatment
mrsa
infect
teicoplanin
linezolid
associ
fewer
side
effect
renal
toxic
addit
consumpt
tigecyclin
increas
inpatientday
inpatientday
howev
although
consumpt
tigecyclin
daptomycin
increas
time
signific
associ
consumpt
antimicrobi
agent
incid
nosocomi
mrsa
infect
studi
period
longterm
studi
need
evalu
trend
hcaimrsa
infect
associ
consumpt
tigecyclin
daptomycin
although
relationship
incid
mrsa
use
blactam
antibiot
fluoroquinolon
investig
studi
focus
associ
consumpt
glycopeptid
linezolid
fusid
acid
incid
infect
due
gramposit
bacteria
studi
found
incid
infect
due
mrsa
significantli
decreas
inpatientday
inpatientday
addit
note
neg
correl
use
teicoplanin
linezolid
incid
hcaimrsa
although
research
need
clarifi
associ
find
suggest
teicoplanin
linezolid
might
exert
protect
effect
emerg
mrsa
also
found
signific
correl
consumpt
vancomycin
glycopeptid
includ
vancomycin
teicoplanin
fusid
acid
incid
hcaimrsa
find
consist
report
previou
studi
addit
consumpt
tigecyclin
daptomycin
associ
incid
hcaimrsa
reason
find
like
due
short
durat
tigecyclin
daptomycin
use
hospit
longer
studi
period
need
clarifi
correl
two
antimicrobi
agent
incid
mrsa
infect
data
show
incid
hcaivr
significantli
increas
studi
period
found
increas
use
teicoplanin
posit
correl
increas
incid
hcaivr
find
consist
previou
studi
contrast
found
neg
correl
use
teicoplanin
incid
hcaimrsa
data
also
show
posit
correl
consumpt
tigecyclin
incid
hcaivr
although
tigecyclin
use
year
studi
strong
posit
correl
use
incid
vre
infect
impli
tigecyclin
administ
caution
studi
sever
limit
although
found
signific
correl
antibiot
use
incid
hcaimrsa
etiolog
behind
emerg
drugresist
bacteria
hospit
complic
select
pressur
widespread
use
antimicrobi
agent
might
one
caus
preval
mrsa
could
affect
multipl
factor
infectioncontrol
measur
hand
hygien
oper
chang
hospit
emerg
sever
acut
respiratori
syndrom
infect
prevent
control
program
ntuh
upgrad
includ
hand
hygien
antibioticcontrol
polici
annual
intens
projectbas
control
program
fact
demonstr
polici
directli
associ
decreas
rate
hcai
bloodstream
infect
ntuh
howev
effect
measur
studi
whether
polici
impact
mrsa
trend
remain
unknown
addit
epidemiolog
surveil
studi
analyz
impact
durat
exposur
antibiot
clonal
spread
resist
bacteria
trend
incid
nosocomi
mrsa
infect
furthermor
overal
ddd
given
antibiot
notori
problemat
denomin
chang
lowdos
usag
specif
group
patient
ie
children
patient
renal
insuffici
therefor
analysi
use
number
prescript
patient
group
would
appropri
howev
impact
limit
studi
specif
patient
group
compris
small
fraction
studi
patient
effect
would
dilut
equal
year
conclus
studi
singl
medic
institut
found
use
teicoplanin
linezolid
significantli
increas
furthermor
found
neg
correl
usag
individu
antibiot
teicoplanin
linezolid
incid
hcaimrsa
howev
also
found
posit
correl
consumpt
teicoplanin
tigecyclin
incid
hcaivr
therefor
strict
implement
infectioncontrol
polici
includ
administr
appropri
antimicrobi
agent
may
posit
correl
decreas
presenc
mrsa
hospit
